Rinvoq ER 30 MG tablet UU 30S
Ended Awarded Last action
- Contract number
- SPE2DR26F1W19
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $21,471
Award facts
- Contract value 100% obligated
- $21,471.44 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $21,471.44 firm fixed-price delivery order to AmerisourceBergen Drug Corp on January 20, 2026, for the supply of RINVOQ ER 30 mg tablets (30-count units), with a completion date of January 21, 2026. This non-set-aside delivery order will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The contract represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s substantial Indefinite Delivery Contract with DLA Troop Support Medical, which is valued at up to $999,999,999.00 and extends through December 2031, serving as a comprehensive global pharmaceutical support vehicle for military healthcare programs.
AmerisourceBergen Drug Corp functions as a critical federal medical vendor specializing in pharmaceutical distribution to military and veteran healthcare systems. The company's broader federal contract portfolio demonstrates extensive capability in supplying brand-name and generic medications across multiple therapeutic domains, including specialty pharmaceuticals, vaccines, and medical supplies. This delivery order for RINVOQ, a prescription medication used in rheumatologic conditions, exemplifies the company's ongoing role in fulfilling pharmaceutical procurement requirements for the Department of Defense healthcare ecosystem through competitively awarded, fixed-price transactions under the DLA's primary pharmaceutical supply contract.
Quick answers
Who was awarded contract SPE2DR26F1W19?
SPE2DR26F1W19 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 20, 2026.
How much is contract SPE2DR26F1W19 worth?
The government has obligated $21,471 on SPE2DR26F1W19.
Is contract SPE2DR26F1W19 an order under another contract?
Yes. SPE2DR26F1W19 is a delivery order under SPE2DR25D2205, an indefinite delivery contract.
Was contract SPE2DR26F1W19 competed?
The extent of competition for SPE2DR26F1W19 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award